[
  {
    "ts": null,
    "headline": "A Fresh Look at Zoetis (ZTS) Valuation After Earnings Beat and New EU Product Approval",
    "summary": "Zoetis, the animal health company, reported higher third quarter earnings and net income for 2025 and reaffirmed its full-year guidance. The company also secured European approval for Portela, expanding its growing monoclonal antibody portfolio for companion animals. See our latest analysis for Zoetis. Despite new product approvals and steady top-line growth, Zoetis shares have seen a sharp downturn, with a 1-year total shareholder return of -31.1% and the share price now sitting at $119.79...",
    "url": "https://finnhub.io/api/news?id=e66571cc9987afa7903df062592d00f26c7a6702670c04a00dc25cca9b580e22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762885194,
      "headline": "A Fresh Look at Zoetis (ZTS) Valuation After Earnings Beat and New EU Product Approval",
      "id": 137449997,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis, the animal health company, reported higher third quarter earnings and net income for 2025 and reaffirmed its full-year guidance. The company also secured European approval for Portela, expanding its growing monoclonal antibody portfolio for companion animals. See our latest analysis for Zoetis. Despite new product approvals and steady top-line growth, Zoetis shares have seen a sharp downturn, with a 1-year total shareholder return of -31.1% and the share price now sitting at $119.79...",
      "url": "https://finnhub.io/api/news?id=e66571cc9987afa7903df062592d00f26c7a6702670c04a00dc25cca9b580e22"
    }
  },
  {
    "ts": null,
    "headline": "RION Launches Rion Vet to Transform Animal Health with First-in-Class Exosome Biologics; Appoints Industry Leader Mark Herthel as CEO; Announces Series A Fulfillment",
    "summary": "ROCHESTER, Minn., November 11, 2025--RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of Rion Vet, a veterinary biotechnology company advancing platelet-derived exosome-based biologics to address major unmet needs in animal health. The company launches with exclusive global rights to RION’s proprietary Purified Exosome Product (PEP™) platform for veterinary use. Rion Vet anticipates bringing its first product, ePE",
    "url": "https://finnhub.io/api/news?id=972c80d24ae4b2856620b68f1df1d44764e16e29435e29a93d242a66164f6d3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762869600,
      "headline": "RION Launches Rion Vet to Transform Animal Health with First-in-Class Exosome Biologics; Appoints Industry Leader Mark Herthel as CEO; Announces Series A Fulfillment",
      "id": 137449089,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "ROCHESTER, Minn., November 11, 2025--RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of Rion Vet, a veterinary biotechnology company advancing platelet-derived exosome-based biologics to address major unmet needs in animal health. The company launches with exclusive global rights to RION’s proprietary Purified Exosome Product (PEP™) platform for veterinary use. Rion Vet anticipates bringing its first product, ePE",
      "url": "https://finnhub.io/api/news?id=972c80d24ae4b2856620b68f1df1d44764e16e29435e29a93d242a66164f6d3a"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Double Up on Right Now",
    "summary": "These healthcare heavyweights have tumbled, causing abnormally high dividend yields.",
    "url": "https://finnhub.io/api/news?id=bab0633a2f4b746a6cb6bf6543a869d8b1d670c8bcb6b27d457208c6f873e874",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762853700,
      "headline": "2 Dividend Stocks to Double Up on Right Now",
      "id": 137448787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "These healthcare heavyweights have tumbled, causing abnormally high dividend yields.",
      "url": "https://finnhub.io/api/news?id=bab0633a2f4b746a6cb6bf6543a869d8b1d670c8bcb6b27d457208c6f873e874"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Zoetis’s Q3 Earnings Call",
    "summary": "Zoetis faced a challenging third quarter, with the market reacting negatively to results that showed flat year-on-year sales and a trim to full-year revenue guidance. Management attributed the muted performance primarily to subdued clinic visits in the U.S. companion animal segment and heightened promotional activity from competitors. CEO Kristin Peck noted, “Growth moderated this quarter driven by a strong year-over-year comp and macro factors, including vet clinic visits and promotional activi",
    "url": "https://finnhub.io/api/news?id=5879fd4643ecbe00d269a3d1448fc825cb6d799ea5de0036a6baf9423341399d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762839257,
      "headline": "The 5 Most Interesting Analyst Questions From Zoetis’s Q3 Earnings Call",
      "id": 137449091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis faced a challenging third quarter, with the market reacting negatively to results that showed flat year-on-year sales and a trim to full-year revenue guidance. Management attributed the muted performance primarily to subdued clinic visits in the U.S. companion animal segment and heightened promotional activity from competitors. CEO Kristin Peck noted, “Growth moderated this quarter driven by a strong year-over-year comp and macro factors, including vet clinic visits and promotional activi",
      "url": "https://finnhub.io/api/news?id=5879fd4643ecbe00d269a3d1448fc825cb6d799ea5de0036a6baf9423341399d"
    }
  }
]